Postbiotics
JP2024530209A5Pending Publication Date: 2025-03-25SOCIETE DES PRODUITS NESTLE SA
0 Cites 0 Cited by
Patent Information
- Application Number
- JP2024508414
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-08-19
- Filing Date
- 2022-08-18
- Publication Date
- 2025-03-25
AI Technical Summary
Technical Problem
Existing solutions for enhancing the expression of anti-inflammatory cytokines like IL-10 are less effective and associated with significant side effects, and viable probiotics have limitations in application.
Method used
Utilizing Bifidobacterium lactis culture supernatant, which significantly increases anti-inflammatory cytokine IL-10 secretion and decreases pro-inflammatory chemokine IL-8 secretion, offering a non-viable probiotic alternative for immunomodulation.
Benefits of technology
The Bifidobacterium lactis culture supernatant effectively enhances IL-10 expression and reduces IL-8 secretion, providing a safer and more effective immunomodulatory effect compared to traditional probiotics.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention provides a Bifidobacterium lactis culture supernatant for use in enhancing expression of anti-inflammatory cytokines and / or reducing expression of pro-inflammatory chemokines in the gastrointestinal tract of a subject having or at risk for an overactive immune system disorder. The present invention also provides a Bifidobacterium lactis culture supernatant for use in enhancing expression of IL-10 in the gastrointestinal tract of a subject having or at risk for an IL-10 mediated disease. The present invention also provides a Bifidobacterium lactis culture supernatant for use in treating or preventing an IL-10 mediated disease by enhancing expression of IL-10 in the gastrointestinal tract of a subject.
Need to check novelty before this filing date? Find Prior Art